drug actions
TRANSCRIPT
![Page 1: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/1.jpg)
PharmacologyPharmacologyPharmacologyPharmacology
Pharmacokinetics
Pharmacodynamics
Pharmacokinetics
Pharmacodynamics
![Page 2: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/2.jpg)
PharmacokineticsPharmacokineticsPharmacokineticsPharmacokinetics
• Time course of drug absorption, distribution, metabolism, excretion
• Time course of drug absorption, distribution, metabolism, excretion
How the drugHow the drugcomes and goes.comes and goes.How the drugHow the drug
comes and goes.comes and goes.
![Page 3: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/3.jpg)
“LADME” is key
Pharmacokinetic ProcessesPharmacokinetic ProcessesPharmacokinetic ProcessesPharmacokinetic Processes
LiberationLiberationLiberationLiberation
AbsorptionAbsorptionAbsorptionAbsorption
DistributionDistributionDistributionDistribution
MetabolismMetabolismMetabolismMetabolism
ExcretionExcretionExcretionExcretion
![Page 4: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/4.jpg)
LiberationLiberationLiberationLiberation
• Applies to drugs given orally
• Components– Release of drug from pill, tablet, capsule– Dissolving of active drug in GI fluids
• Applies to drugs given orally
• Components– Release of drug from pill, tablet, capsule– Dissolving of active drug in GI fluids
Ex: Enteric coated Ex: Enteric coated aspirin slows absorption in aspirin slows absorption in
stomach vs non-coatedstomach vs non-coated
Ex: Enteric coated Ex: Enteric coated aspirin slows absorption in aspirin slows absorption in
stomach vs non-coatedstomach vs non-coated
![Page 5: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/5.jpg)
AbsorptionAbsorptionAbsorptionAbsorption
• Movement from administration site into circulation
• Movement from administration site into circulation
![Page 6: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/6.jpg)
Factors Affecting Liberation/AbsorptionFactors Affecting Liberation/AbsorptionFactors Affecting Liberation/AbsorptionFactors Affecting Liberation/Absorption
• Formulation factors– Tablet disintegration
– Inert ingredient / solvent effects
– Solubility
– Drug pH
– Concentration
• Formulation factors– Tablet disintegration
– Inert ingredient / solvent effects
– Solubility
– Drug pH
– Concentration
• Patient factors– Absorbing surface
– Blood flow
– Environmental pH
– Disease states
– Interactions with food, other drugs
• Patient factors– Absorbing surface
– Blood flow
– Environmental pH
– Disease states
– Interactions with food, other drugs
![Page 7: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/7.jpg)
Lipid Bilayer
Small, uncharged
Large, uncharged
Small charged ions
H2O, urea, CO2, O2, N2
Glucose Sucrose
H+, Na+, K+, Ca2+, Cl-, HCO3
-
DENIED!
DENIED!
Swoosh!
Hydrophobic Tails
Hydrophobic Tails
Hydrophilic Heads
Hydrophilic Heads
Membranes and AbsorptionMembranes and AbsorptionMembranes and AbsorptionMembranes and Absorption
![Page 8: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/8.jpg)
LaChatlier’s PrincipleLaChatlier’s PrincipleLaChatlier’s PrincipleLaChatlier’s Principle
a.k.a. Mass Actiona.k.a. Mass Action A reaction at equilibriumresponds to stress in away to best return to
equilibrium
A reaction at equilibriumresponds to stress in away to best return to
equilibrium
4 Na+ 4 Cl_ 4 NaCl+
Systemat
Equilibrium
Systemat
Equilibrium
![Page 9: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/9.jpg)
4 4 Cl- 4 NaCl+ 12 NaCl
1. System at equilibrium1. System at equilibrium
by 8
2. Stress applied to system2. Stress applied to system3. System responds to stress3. System responds to stress
System not atSystem not atequilibrium!equilibrium!
System not atSystem not atequilibrium!equilibrium!
4 Na+
by 4 by 4
8 Na+ 8 Cl- 8 NaCl
4. System returns to equilibrium!4. System returns to equilibrium!
4 NaCl dissociate
An example ofAn example ofLaChatlier’s LaChatlier’s
PrinciplePrinciple
![Page 10: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/10.jpg)
IonizationIonizationIonizationIonization
AcidsAcids Release/Donate H+Release/Donate H+
HA H+ + A-
BasesBases Bind/Accept H+Bind/Accept H+
H+ + B- HB
Ionizedform
Ionizedform
Non-ionizedform
Non-ionizedform
![Page 11: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/11.jpg)
If we put an acidic drug in an environment with a lot of H+ (low pH) what will this equilibrium do?
If we put an acidic drug in an environment with a lot of H+ (low pH) what will this equilibrium do?
Environmental pH and Environmental pH and IonizationIonizationEnvironmental pH and Environmental pH and IonizationIonization
HA H+ + A-
System at EquilibriumSystem at Equilibrium H+ from acid environment H+ from acid environment
HAHAHAHA
Non-ionized form predominates!Non-ionized form predominates!
![Page 12: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/12.jpg)
Aspirin is an acidic drug. In the stomach will it exist mostly in ionized or non-ionized form?
Aspirin is an acidic drug. In the stomach will it exist mostly in ionized or non-ionized form?
NON-IONIZED
A real live, actual clinical A real live, actual clinical question...question...A real live, actual clinical A real live, actual clinical question...question...
Why?Why?
![Page 13: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/13.jpg)
Lipid Bilayer
How will this affect aspirin How will this affect aspirin absorption?absorption?How will this affect aspirin How will this affect aspirin absorption?absorption?
Ionized form (charged)
Ionized form (charged) A-
Ionized form (uncharged)
Ionized form (uncharged) HA HA
![Page 14: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/14.jpg)
Moral of the story...Moral of the story...Moral of the story...Moral of the story...
Acidic drugs are best absorbed from acidic environments
Acidic drugs are best absorbed from acidic environments
Basic drugs are best absorbed from
basic environments
Basic drugs are best absorbed from
basic environments
![Page 15: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/15.jpg)
So...So...So...So...
To absorption of an acidic drug…
acidify the environment
To absorption of an acidic drug…
acidify the environment
To absorption of an acidic drug…
alkalanize the environment...
To absorption of an acidic drug…
alkalanize the environment...
![Page 16: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/16.jpg)
DistributionDistributionDistributionDistribution
• Rate of perfusion
• Plasma protein (albumin) binding
• Accumulation in tissues
• Ability to cross membranes– Blood-brain barrier– Placental barrier
• Rate of perfusion
• Plasma protein (albumin) binding
• Accumulation in tissues
• Ability to cross membranes– Blood-brain barrier– Placental barrier
![Page 17: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/17.jpg)
warfarin (Coumadin) is highly protein warfarin (Coumadin) is highly protein bound (99%). Aspirin binds to the same bound (99%). Aspirin binds to the same site on serum proteins as does site on serum proteins as does Coumadin. If a patient on Coumadin Coumadin. If a patient on Coumadin also takes aspirin, what will happen?also takes aspirin, what will happen?
warfarin (Coumadin) is highly protein warfarin (Coumadin) is highly protein bound (99%). Aspirin binds to the same bound (99%). Aspirin binds to the same site on serum proteins as does site on serum proteins as does Coumadin. If a patient on Coumadin Coumadin. If a patient on Coumadin also takes aspirin, what will happen?also takes aspirin, what will happen?
The available Coumadin will increase.
Plasma Protein BindingPlasma Protein BindingPlasma Protein BindingPlasma Protein Binding
1) Why?2) Why do we care?
1) Why?2) Why do we care?
![Page 18: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/18.jpg)
The blood brain barrier consists of The blood brain barrier consists of cell tightly packed around the cell tightly packed around the capillaries of the CNS. What capillaries of the CNS. What characteristics must a drug possess characteristics must a drug possess to easily cross this barrier?to easily cross this barrier?
The blood brain barrier consists of The blood brain barrier consists of cell tightly packed around the cell tightly packed around the capillaries of the CNS. What capillaries of the CNS. What characteristics must a drug possess characteristics must a drug possess to easily cross this barrier?to easily cross this barrier?
Non-protein bound, non-ionized, and highly lipid
soluble
Blood-Brain BarrierBlood-Brain BarrierBlood-Brain BarrierBlood-Brain Barrier
![Page 19: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/19.jpg)
Metabolism Metabolism (Biotransformation)(Biotransformation)Metabolism Metabolism (Biotransformation)(Biotransformation)• Two effects
– Transformation to less active metabolite– Enhancement of solubility
• Liver = primary site
• Liver disease– Slows metabolism– Prolongs effects
• Two effects– Transformation to less active metabolite– Enhancement of solubility
• Liver = primary site
• Liver disease– Slows metabolism– Prolongs effects
![Page 20: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/20.jpg)
Hepatic ‘First-Pass’ Hepatic ‘First-Pass’ MetabolismMetabolismHepatic ‘First-Pass’ Hepatic ‘First-Pass’ MetabolismMetabolism• Affects orally administered drugs
• Metabolism of drug by liver before drug reaches systemic circulation
• Drug absorbed into portal circulation, must pass through liver to reach systemic circulation
• May reduce availability of drug
• Affects orally administered drugs
• Metabolism of drug by liver before drug reaches systemic circulation
• Drug absorbed into portal circulation, must pass through liver to reach systemic circulation
• May reduce availability of drug
![Page 21: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/21.jpg)
EliminationEliminationEliminationElimination
• Kidneys = primary site– Mechanisms dependent upon:
• Passive glomerular filtration
• Active tubular transport
– Partial reabsorption– Hemodialysis
• Renal disease– Slows excretion– Prolongs effects
• Kidneys = primary site– Mechanisms dependent upon:
• Passive glomerular filtration
• Active tubular transport
– Partial reabsorption– Hemodialysis
• Renal disease– Slows excretion– Prolongs effects
![Page 22: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/22.jpg)
Active Tubular TransportActive Tubular TransportActive Tubular TransportActive Tubular Transport
Probenecid is moved into the urine by the same transport pump that moves many antibiotics. Why is probenecid sometimes given as an adjunct to antibiotic therapy?
Probenecid is moved into the urine by the same transport pump that moves many antibiotics. Why is probenecid sometimes given as an adjunct to antibiotic therapy?
It competes with the antibiotic at the pump
and slows its excretion.
![Page 23: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/23.jpg)
A patient has overdosed on A patient has overdosed on phenobartital. Phenobarbital is an acid. phenobartital. Phenobarbital is an acid. If we ‘alkalinalize’ the urine by giving If we ‘alkalinalize’ the urine by giving bicarbonate what will happen to the bicarbonate what will happen to the phenobarbital molecules as they are phenobarbital molecules as they are filtered through the renal tubules?filtered through the renal tubules?
A patient has overdosed on A patient has overdosed on phenobartital. Phenobarbital is an acid. phenobartital. Phenobarbital is an acid. If we ‘alkalinalize’ the urine by giving If we ‘alkalinalize’ the urine by giving bicarbonate what will happen to the bicarbonate what will happen to the phenobarbital molecules as they are phenobarbital molecules as they are filtered through the renal tubules?filtered through the renal tubules?
They will ionize...
Urine pH and EliminationUrine pH and EliminationUrine pH and EliminationUrine pH and Elimination
![Page 24: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/24.jpg)
Non-ionized
HA H+ + A-
How will this affect phenobarbital How will this affect phenobarbital reabsorption by the kidney?reabsorption by the kidney?How will this affect phenobarbital How will this affect phenobarbital reabsorption by the kidney?reabsorption by the kidney?
Decreased reabsorptionDecreased reabsorption
Increased eliminationIncreased elimination
Ionized
![Page 25: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/25.jpg)
EliminationEliminationEliminationElimination
• Other sources– Feces– Exhaled air– Breast milk– Sweat
• Other sources– Feces– Exhaled air– Breast milk– Sweat
![Page 26: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/26.jpg)
Biological Half-life (t Biological Half-life (t 1/21/2))Biological Half-life (t Biological Half-life (t 1/21/2))
• Amount of time to eliminate 1/2 of total drug amount
• Shorter t 1/2 may need more frequent doses
• Hepatic disease may increase t1/2
• Amount of time to eliminate 1/2 of total drug amount
• Shorter t 1/2 may need more frequent doses
• Hepatic disease may increase t1/2
![Page 27: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/27.jpg)
A drug has a half life of 10 seconds. You A drug has a half life of 10 seconds. You give a patient a dose of 6mg. After 30 give a patient a dose of 6mg. After 30 seconds how much of the drug remains?seconds how much of the drug remains?
A drug has a half life of 10 seconds. You A drug has a half life of 10 seconds. You give a patient a dose of 6mg. After 30 give a patient a dose of 6mg. After 30 seconds how much of the drug remains?seconds how much of the drug remains?
TimeTime AmountAmount
0 sec0 sec 6 mg6 mg
10 sec10 sec 3 mg3 mg
20 sec20 sec 1.5 mg1.5 mg
30 sec30 sec 0.75 mg0.75 mg
![Page 28: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/28.jpg)
Administration RoutesAdministration RoutesAdministration RoutesAdministration Routes
• Intravenous– Fastest, Most dangerous
• Endotracheal– Lidocaine, atropine, narcan, epinephrine
• Inhalation– Bronchodilators via nebulizers
• Transmucosal– Rectal or sublingual
• Intravenous– Fastest, Most dangerous
• Endotracheal– Lidocaine, atropine, narcan, epinephrine
• Inhalation– Bronchodilators via nebulizers
• Transmucosal– Rectal or sublingual
![Page 29: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/29.jpg)
Administration RoutesAdministration RoutesAdministration RoutesAdministration Routes
• Intramuscular– Depends on perfusion quality
• Subcutaneous– Depends on perfusion quality
• Oral– Slow, unpredictable – Little prehospital use
• Intramuscular– Depends on perfusion quality
• Subcutaneous– Depends on perfusion quality
• Oral– Slow, unpredictable – Little prehospital use
![Page 30: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/30.jpg)
PharmacodynamicsPharmacodynamicsPharmacodynamicsPharmacodynamics
• The biochemical and physiologic mechanisms of drug action
• The biochemical and physiologic mechanisms of drug action
What the drugWhat the drugdoes when it gets there.does when it gets there.
What the drugWhat the drugdoes when it gets there.does when it gets there.
![Page 31: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/31.jpg)
Drug MechanismsDrug MechanismsDrug MechanismsDrug Mechanisms
• Receptor interactions
• Non-receptor mechanisms
• Receptor interactions
• Non-receptor mechanisms
![Page 32: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/32.jpg)
Receptor InteractionsReceptor InteractionsReceptor InteractionsReceptor Interactions
Agonist Receptor
Agonist-Receptor
Interaction
Lock and key mechanism
![Page 33: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/33.jpg)
Receptor InteractionsReceptor InteractionsReceptor InteractionsReceptor Interactions
Receptor
Perfect Fit!
Induced Fit
![Page 34: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/34.jpg)
Receptor InteractionsReceptor InteractionsReceptor InteractionsReceptor Interactions
Antagonist Receptor
Antagonist-Receptor
ComplexDENIED!
CompetitiveInhibition
![Page 35: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/35.jpg)
Agonist Receptor
Antagonist
‘Inhibited’-ReceptorDENIED!
Receptor InteractionsReceptor InteractionsReceptor InteractionsReceptor Interactions
Non-competitive Inhibition
![Page 36: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/36.jpg)
Non-receptor MechanismsNon-receptor MechanismsNon-receptor MechanismsNon-receptor Mechanisms
• Actions on Enzymes– Enzymes = Biological catalysts
• Speed chemical reactions
• Are not changed themselves
– Drugs altering enzyme activity alter processes catalyzed by the enzymes
– Examples• Cholinesterase inhibitors
• Monoamine oxidase inhibitors
• Actions on Enzymes– Enzymes = Biological catalysts
• Speed chemical reactions
• Are not changed themselves
– Drugs altering enzyme activity alter processes catalyzed by the enzymes
– Examples• Cholinesterase inhibitors
• Monoamine oxidase inhibitors
![Page 37: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/37.jpg)
Non-receptor MechanismsNon-receptor MechanismsNon-receptor MechanismsNon-receptor Mechanisms
• Changing Physical Properties– Mannitol– Changes osmotic balance across membranes– Causes urine production (osmotic diuresis)
• Changing Physical Properties– Mannitol– Changes osmotic balance across membranes– Causes urine production (osmotic diuresis)
![Page 38: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/38.jpg)
Non-receptor MechanismsNon-receptor MechanismsNon-receptor MechanismsNon-receptor Mechanisms
• Changing Cell Membrane Permeability– Lidocaine
• Blocks sodium channels
– Verapamil, nefedipine• Block calcium channels
– Bretylium• Blocks potassium channels
– Adenosine• Opens potassium channels
• Changing Cell Membrane Permeability– Lidocaine
• Blocks sodium channels
– Verapamil, nefedipine• Block calcium channels
– Bretylium• Blocks potassium channels
– Adenosine• Opens potassium channels
![Page 39: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/39.jpg)
Non-receptor MechanismsNon-receptor MechanismsNon-receptor MechanismsNon-receptor Mechanisms
• Combining With Other Chemicals– Antacids– Antiseptic effects of alcohol, phenol– Chelation of heavy metals
• Combining With Other Chemicals– Antacids– Antiseptic effects of alcohol, phenol– Chelation of heavy metals
![Page 40: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/40.jpg)
Non-receptor MechanismsNon-receptor MechanismsNon-receptor MechanismsNon-receptor Mechanisms
• Anti-metabolites– Enter biochemical reactions in place of normal
substrate “competitors”– Result in biologically inactive product– Examples
• Some anti-neoplastics
• Some anti-infectives
• Anti-metabolites– Enter biochemical reactions in place of normal
substrate “competitors”– Result in biologically inactive product– Examples
• Some anti-neoplastics
• Some anti-infectives
![Page 41: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/41.jpg)
Drug Response RelationshipsDrug Response RelationshipsDrug Response RelationshipsDrug Response Relationships
• Time Response
• Dose Response
• Time Response
• Dose Response
![Page 42: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/42.jpg)
Latency Duration of Response
Maximal (Peak) Effect
Effect/
Response
Time
Time Response RelationshipsTime Response RelationshipsTime Response RelationshipsTime Response Relationships
![Page 43: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/43.jpg)
Effect/
Response
Time
IVSC
IM
Time Response RelationshipsTime Response RelationshipsTime Response RelationshipsTime Response Relationships
![Page 44: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/44.jpg)
Dose Response RelationshipsDose Response RelationshipsDose Response RelationshipsDose Response Relationships
• Potency– Absolute amount of drug required to produce
an effect– More potent drug is the one that requires lower
dose to cause same effect
• Potency– Absolute amount of drug required to produce
an effect– More potent drug is the one that requires lower
dose to cause same effect
![Page 45: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/45.jpg)
PotencyPotencyPotencyPotency
Effect
Dose
A B
Which drug is more potent?
A!A!Why?Why?
TherapeuticEffect
![Page 46: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/46.jpg)
Dose Response RelationshipsDose Response RelationshipsDose Response RelationshipsDose Response Relationships
• Threshold (minimal) dose– Least amount needed to produce desired effects
• Maximum effect– Greatest response produced regardless of dose
used
• Threshold (minimal) dose– Least amount needed to produce desired effects
• Maximum effect– Greatest response produced regardless of dose
used
![Page 47: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/47.jpg)
Dose Response RelationshipsDose Response Relationships
Which drug has the lower threshold dose?
Effect
Dose
A
B
Which has the greater maximum effect?
AA
BB
TherapeuticEffect
![Page 48: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/48.jpg)
Dose Response RelationshipsDose Response RelationshipsDose Response RelationshipsDose Response Relationships
• Loading dose– Bolus of drug given initially to rapidly reach
therapeutic levels
• Maintenance dose– Lower dose of drug given continuously or at
regular intervals to maintain therapeutic levels
• Loading dose– Bolus of drug given initially to rapidly reach
therapeutic levels
• Maintenance dose– Lower dose of drug given continuously or at
regular intervals to maintain therapeutic levels
![Page 49: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/49.jpg)
Therapeutic IndexTherapeutic IndexTherapeutic IndexTherapeutic Index
• Drug’s safety margin
• Must be >1 for drug to be usable
• Digitalis has a TI of 2
• Penicillin has TI of >100
• Drug’s safety margin
• Must be >1 for drug to be usable
• Digitalis has a TI of 2
• Penicillin has TI of >100
50
50
ED
LDTI
50
50
ED
LDTI
![Page 50: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/50.jpg)
Therapeutic IndexTherapeutic IndexTherapeutic IndexTherapeutic Index
Why don’t we use adrug with a TI <1?
Why don’t we use adrug with a TI <1?
ED50 < LD50 = Very Bad!ED50 < LD50 = Very Bad!ED50 < LD50 = Very Bad!ED50 < LD50 = Very Bad!
![Page 51: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/51.jpg)
Factors Altering Drug Factors Altering Drug ResponsesResponsesFactors Altering Drug Factors Altering Drug ResponsesResponses• Age
– Pediatric or geriatric– Immature or decreased hepatic, renal function
• Weight– Big patients “spread” drug over larger volume
• Gender– Difference in sizes– Difference in fat/water distribution
• Age– Pediatric or geriatric– Immature or decreased hepatic, renal function
• Weight– Big patients “spread” drug over larger volume
• Gender– Difference in sizes– Difference in fat/water distribution
![Page 52: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/52.jpg)
Factors Altering Drug Factors Altering Drug ResponsesResponsesFactors Altering Drug Factors Altering Drug ResponsesResponses• Environment
– Heat or cold– Presence or real or perceived threats
• Fever
• Shock
• Environment– Heat or cold– Presence or real or perceived threats
• Fever
• Shock
![Page 53: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/53.jpg)
Factors Altering Drug Factors Altering Drug ResponsesResponsesFactors Altering Drug Factors Altering Drug ResponsesResponses• Pathology
– Drug may aggravate underlying pathology– Hepatic disease may slow drug metabolism– Renal disease may slow drug elimination– Acid/base abnormalities may change drug
absorption or elimination
• Pathology– Drug may aggravate underlying pathology– Hepatic disease may slow drug metabolism– Renal disease may slow drug elimination– Acid/base abnormalities may change drug
absorption or elimination
![Page 54: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/54.jpg)
Influencing factorsInfluencing factorsInfluencing factorsInfluencing factors
• Genetic effects– Lack of specific enzymes– Lower metabolic rate
• Psychological factors– Placebo effect
• Genetic effects– Lack of specific enzymes– Lower metabolic rate
• Psychological factors– Placebo effect
![Page 55: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/55.jpg)
Pediatric PatientsPediatric PatientsPediatric PatientsPediatric Patients
• Higher proportion of water
• Lower plasma protein levels– More available drug
• Immature liver/kidneys– Liver often metabolizes more slowly– Kidneys may excrete more slowly
• Higher proportion of water
• Lower plasma protein levels– More available drug
• Immature liver/kidneys– Liver often metabolizes more slowly– Kidneys may excrete more slowly
![Page 56: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/56.jpg)
Geriatric PatientsGeriatric PatientsGeriatric PatientsGeriatric Patients
• Chronic disease states• Decreased plasma
protein binding• Slower metabolism• Slower excretion
• Chronic disease states• Decreased plasma
protein binding• Slower metabolism• Slower excretion
• Dietary deficiencies• Use of multiple
medications• Lack of compliance
• Dietary deficiencies• Use of multiple
medications• Lack of compliance
![Page 57: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/57.jpg)
Site of ActionDosage Effects
PlasmaConcen.
Pharmacokinetics Pharmacodynamics
www.freelivedoctor.com
![Page 58: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/58.jpg)
Dose
Pla
sma
Co
nce
ntr
atio
n
0 1 2 3 4 5 6 7 8 90
2
4
6
8
10
12
TOXIC RANGE
THERAPEUTIC RANGE
SUB-THERAPEUTIC
www.freelivedoctor.com
![Page 59: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/59.jpg)
DISPOSITION OF DRUGS
The disposition of chemicals entering the body (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill, 1996).
www.freelivedoctor.com
![Page 60: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/60.jpg)
Bound Free Free Bound
LOCUS OF ACTION
“RECEPTORS”TISSUE RESERVOIRS
SYSTEMIC CIRCULATION
Free Drug
Bound Drug
ABSORPTION EXCRETION
BIOTRANSFORMATIONwww.freelivedoctor.com
![Page 61: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/61.jpg)
Plasma concentration vs. time profile of a single dose of a drug ingested orally
0
2
4
6
8
10
12
14
0 5 10 15 20
TIME (hours)
Pla
sm
a C
on
cen
tra
tio
n
www.freelivedoctor.com
![Page 62: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/62.jpg)
Dose
Pla
sma
Co
nce
ntr
atio
n
0 1 2 3 4 5 6 7 8 90
2
4
6
8
10
12
TOXIC RANGE
THERAPEUTIC RANGE
SUB-THERAPEUTIC
www.freelivedoctor.com
![Page 63: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/63.jpg)
Bound Free Free Bound
LOCUS OF ACTION
“RECEPTORS”TISSUE RESERVOIRS
SYSTEMIC CIRCULATION
Free Drug
Bound Drug
ABSORPTION EXCRETION
BIOTRANSFORMATIONwww.freelivedoctor.com
![Page 64: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/64.jpg)
Bioavailability
Definition: the fraction of the administered dose reaching the systemic circulation
for i.v.: 100%for non i.v.: ranges from 0 to 100%
e.g. lidocaine bioavailability 35% due to destruction in gastric acid and liver metabolism
First Pass Effect
www.freelivedoctor.com
![Page 65: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/65.jpg)
BioavailabilityBioavailabilityBioavailabilityBioavailability
Dose
Destroyed in gut
Notabsorbed
Destroyed by gut wall
Destroyedby liver
tosystemiccirculation
www.freelivedoctor.com
![Page 66: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/66.jpg)
PRINCIPLEPRINCIPLE
For drugs taken by routes other than the i.v. route, the extent of absorption and the bioavailability must be understood in order to determine what dose will induce the desired therapeutic effect. It will also explain why the same dose may cause a therapeutic effect by one route but a toxic or no effect by another.
www.freelivedoctor.com
![Page 67: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/67.jpg)
Drugs appear to distribute in the body as if it were a single compartment. The magnitude of the drug’s distribution is given by the apparent volume of distribution (Vd).
Vd = Amount of drug in body ÷ Concentration in Plasma
PRINCIPLEPRINCIPLE
(Apparent) Volume of Distribution:Volume into which a drug appears to distribute with a concentration equal to its plasma concentration
www.freelivedoctor.com
![Page 68: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/68.jpg)
www.freelivedoctor.com
![Page 69: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/69.jpg)
Drug L/Kg L/70 kg
Sulfisoxazole 0.16 11.2
Phenytoin 0.63 44.1
Phenobarbital 0.55 38.5
Diazepam 2.4 168
Digoxin 7 490
Examples of apparent Vd’s for Examples of apparent Vd’s for some drugssome drugsExamples of apparent Vd’s for Examples of apparent Vd’s for some drugssome drugs
www.freelivedoctor.com
![Page 70: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/70.jpg)
K IDNEYf iltra tion
secre tion( rea bsorp tion )
LIVERm etabo lism
secre tion
LU NGSexha lation
O THERSm othe r's m ilk
sw ea t, sa liva e tc.
Eliminationof drugs from the body
MAJOR
MINOR
www.freelivedoctor.com
![Page 71: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/71.jpg)
Elimination by the KidneyElimination by the KidneyElimination by the KidneyElimination by the Kidney
• Excretion - major1) glomerular filtrationglomerular structure, size constraints,
protein binding
2) tubular reabsorption/secretion- acidification/alkalinization,- active transport, competitive/saturable,
organic acids/bases - protein binding
• Metabolism - minor
• Excretion - major1) glomerular filtrationglomerular structure, size constraints,
protein binding
2) tubular reabsorption/secretion- acidification/alkalinization,- active transport, competitive/saturable,
organic acids/bases - protein binding
• Metabolism - minor
www.freelivedoctor.com
![Page 72: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/72.jpg)
Elimination by the LiverElimination by the LiverElimination by the LiverElimination by the Liver
• Metabolism - major1) Phase I and II reactions
2) Function: change a lipid soluble to more water soluble molecule to excrete in kidney
3) Possibility of active metabolites with same or different properties as parent molecule
• Biliary Secretion – active transport, 4 categories
• Metabolism - major1) Phase I and II reactions
2) Function: change a lipid soluble to more water soluble molecule to excrete in kidney
3) Possibility of active metabolites with same or different properties as parent molecule
• Biliary Secretion – active transport, 4 categories
www.freelivedoctor.com
![Page 73: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/73.jpg)
The enterohepatic shuntThe enterohepatic shuntThe enterohepatic shuntThe enterohepatic shunt
Portal circulation
Liver
gall bladder
Gut
Bile
duct
Drug
Biotransformation;glucuronide produced
Bile formation
Hydrolysis bybeta glucuronidase
www.freelivedoctor.com
![Page 74: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/74.jpg)
Dose
Pla
sma
Co
nce
ntr
atio
n
0 1 2 3 4 5 6 7 8 90
2
4
6
8
10
12
TOXIC RANGE
THERAPEUTIC RANGE
SUB-THERAPEUTIC
www.freelivedoctor.com
![Page 75: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/75.jpg)
0
2
4
6
8
10
12
14
0 5 10 15 20
TIME (hours)
Pla
sma
con
cen
trat
ion
Influence of Variations in Relative Rates of Absorption and Elimination on Plasma Concentration of an Orally Administered Drug
Ka/Ke=10
Ka/Ke=0.1
Ka/Ke=0.01
Ka/Ke=1
www.freelivedoctor.com
![Page 76: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/76.jpg)
EliminationEliminationEliminationElimination
• Zero order: constant rate of elimination irrespective of plasma concentration.
• First order: rate of elimination proportional to plasma concentration. Constant Fraction of drug eliminated per unit time.
Rate of elimination ∝ AmountRate of elimination = K x Amount
• Zero order: constant rate of elimination irrespective of plasma concentration.
• First order: rate of elimination proportional to plasma concentration. Constant Fraction of drug eliminated per unit time.
Rate of elimination ∝ AmountRate of elimination = K x Amount
www.freelivedoctor.com
![Page 77: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/77.jpg)
Zero Order EliminationZero Order Elimination Pharmacokinetics of EthanolPharmacokinetics of Ethanol
Zero Order EliminationZero Order Elimination Pharmacokinetics of EthanolPharmacokinetics of Ethanol
• Ethanol is distributed in total body water.• Mild intoxication at 1 mg/ml in plasma.• How much should be ingested to reach it?
Answer: 42 g or 56 ml of pure ethanol (VdxC)Or 120 ml of a strong alcoholic drink like whiskey
• Ethanol has a constant elimination rate = 10 ml/h• To maintain mild intoxication, at what rate must ethanol be taken
now? at 10 ml/h of pure ethanol, or 20 ml/h of drink.
• Ethanol is distributed in total body water.• Mild intoxication at 1 mg/ml in plasma.• How much should be ingested to reach it?
Answer: 42 g or 56 ml of pure ethanol (VdxC)Or 120 ml of a strong alcoholic drink like whiskey
• Ethanol has a constant elimination rate = 10 ml/h• To maintain mild intoxication, at what rate must ethanol be taken
now? at 10 ml/h of pure ethanol, or 20 ml/h of drink.
Rarely Done DRUNKENNESS Coma Death
www.freelivedoctor.com
![Page 78: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/78.jpg)
0
2
4
6
8
10
12
14
0 5 10 15 20
TIME (hours)
Pla
sma
con
cen
trat
ion Ct = C0 . e – Kel •t
lnCt = lnC0 – Kel • t
logCt = logC0 – Kel •t 2.3
DC/dt = – k•C
y = b – a.x
First Order EliminationFirst Order EliminationFirst Order EliminationFirst Order Elimination
dA/dt A∝ DA/dt = – k•A
www.freelivedoctor.com
![Page 79: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/79.jpg)
Time
Pla
sma
Co
nce
ntr
atio
n
0 1 2 3 4 5 61
10
100
1000
10000
First Order Elimination
logCt = logC0 - Kel . t 2.303
www.freelivedoctor.com
![Page 80: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/80.jpg)
Time
Pla
sm
a C
on
ce
ntr
ati
on
0 1 2 3 4 5 6
1
10
100
1000
10000
C0
Distribution equilibrium
Elimination only
Distribution and Elimination
Plasma Concentration Profile after Plasma Concentration Profile after a Single I.V. Injectiona Single I.V. InjectionPlasma Concentration Profile after Plasma Concentration Profile after a Single I.V. Injectiona Single I.V. Injection
www.freelivedoctor.com
![Page 81: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/81.jpg)
lnCt = lnCo – Kel.t
When t = 0, C = C0, i.e., the concentration at time zero when distribution is complete and elimination has not started yet. Use this value and the dose to calculate Vd.
Vd = Dose/C0
www.freelivedoctor.com
![Page 82: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/82.jpg)
lnCt = lnC0 – Kel.t
When Ct = ½ C0, then Kel.t = 0.693. This is the time for the plasma concentration to reach half the original, i.e., the half-life of elimination.
t1/2 = 0.693/Kel
www.freelivedoctor.com
![Page 83: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/83.jpg)
PRINCIPLEPRINCIPLEPRINCIPLEPRINCIPLE
Elimination of drugs from the body usually follows first order kinetics with a characteristic half-life (t1/2) and fractional rate constant (Kel).
Elimination of drugs from the body usually follows first order kinetics with a characteristic half-life (t1/2) and fractional rate constant (Kel).
www.freelivedoctor.com
![Page 84: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/84.jpg)
First Order EliminationFirst Order EliminationFirst Order EliminationFirst Order Elimination
• Clearance: volume of plasma cleared of drug per unit time.Clearance = Rate of elimination ÷ plasma conc.
• Half-life of elimination: time for plasma conc. to decrease by half.
Useful in estimating: - time to reach steady state concentration. - time for plasma concentration to fall after dosing
is stopped.
• Clearance: volume of plasma cleared of drug per unit time.Clearance = Rate of elimination ÷ plasma conc.
• Half-life of elimination: time for plasma conc. to decrease by half.
Useful in estimating: - time to reach steady state concentration. - time for plasma concentration to fall after dosing
is stopped.
www.freelivedoctor.com
![Page 85: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/85.jpg)
Rate of elimination = Kel x Amount in bodyRate of elimination = CL x Plasma Concentration
Therefore,Kel x Amount = CL x Concentration
Kel = CL/Vd
0.693/t1/2 = CL/Vd
t1/2 = 0.693 x Vd/CLwww.freelivedoctor.com
![Page 86: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/86.jpg)
PRINCIPLEPRINCIPLEPRINCIPLEPRINCIPLE
The half-life of elimination of a drug (and
its residence in the body) depends on its
clearance and its volume of distribution
t1/2 is proportional to Vd
t1/2 is inversely proportional to CL
The half-life of elimination of a drug (and
its residence in the body) depends on its
clearance and its volume of distribution
t1/2 is proportional to Vd
t1/2 is inversely proportional to CL
t1/2 = 0.693 x Vd/CL
www.freelivedoctor.com
![Page 87: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/87.jpg)
Multiple dosingMultiple dosingMultiple dosingMultiple dosing
• On continuous steady administration of a drug, plasma concentration will rise fast at first then more slowly and reach a plateau, where:
rate of administration = rate of elimination ie. steady state is reached.
• Therefore, at steady state:Dose (Rate of Administration) = clearance x plasma conc.
OrIf you aim at a target plasma level and you know the
clearance, you can calculate the dose required.
• On continuous steady administration of a drug, plasma concentration will rise fast at first then more slowly and reach a plateau, where:
rate of administration = rate of elimination ie. steady state is reached.
• Therefore, at steady state:Dose (Rate of Administration) = clearance x plasma conc.
OrIf you aim at a target plasma level and you know the
clearance, you can calculate the dose required.
www.freelivedoctor.com
![Page 88: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/88.jpg)
Constant Rate of Administration (i.v.)zz
www.freelivedoctor.com
![Page 89: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/89.jpg)
0
1
2
3
4
5
6
7
0 5 10 15 20 25 30
Time
Pla
sma
Co
nce
ntr
atio
n
Repeated doses –Maintenance dose
Therapeutic level
Single dose – Loading dose
www.freelivedoctor.com
![Page 90: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/90.jpg)
Concentration due to a single dose
Concentration due to repeated doses
The time to reach steady state is ~4 t1/2’s
www.freelivedoctor.com
![Page 91: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/91.jpg)
Pharmacokinetic parametersPharmacokinetic parametersPharmacokinetic parametersPharmacokinetic parameters
• Volume of distribution Vd = DOSE / C0
• Plasma clearance Cl = Kel .Vd
• plasma half-life t1/2 = 0.693 / Kel
• Bioavailability (AUC)x / (AUC)iv
• Volume of distribution Vd = DOSE / C0
• Plasma clearance Cl = Kel .Vd
• plasma half-life t1/2 = 0.693 / Kel
• Bioavailability (AUC)x / (AUC)iv
Get equation of regression line; from it get Kel, C0 , and AUC
www.freelivedoctor.com
![Page 92: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/92.jpg)
But C x dt = small area under the curve. For total amount eliminated (which is the total given, or the dose, if i.v.), add all the small areas = AUC. Dose = CL x AUC and Dose x F = CL x AUC
dC/dt = CL x C
dC = CL x C x dt
www.freelivedoctor.com
![Page 93: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/93.jpg)
0
10
20
30
40
50
60
70
0 2 4 6 8 10
Pla
sma
con
cen
trat
ion
Time (hours)
Bioavailability (AUC)o
(AUC)iv
=
i.v. route
oral route
www.freelivedoctor.com
![Page 94: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/94.jpg)
Daily Dose (mg/kg)
Pla
sma
Dru
gC
on
cen
trat
ion
(m
g/L
)
0 5 10 150
10
20
30
40
50
60
Variability in PharmacokineticsVariability in PharmacokineticsVariability in PharmacokineticsVariability in Pharmacokinetics
www.freelivedoctor.com
![Page 95: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/95.jpg)
PRINCIPLEPRINCIPLEPRINCIPLEPRINCIPLE
The absorption, distribution and elimination of a drug are qualitatively similar in all
individuals. However, for several reasons, the quantitative aspects may differ considerably. Each person must be considered individually
and doses adjusted accordingly.
The absorption, distribution and elimination of a drug are qualitatively similar in all
individuals. However, for several reasons, the quantitative aspects may differ considerably. Each person must be considered individually
and doses adjusted accordingly.
www.freelivedoctor.com
![Page 96: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/96.jpg)
Site of ActionDosage Effects
PlasmaConcen.
Pharmacokinetics Pharmacodynamics
www.freelivedoctor.com
![Page 97: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/97.jpg)
Bound Free Free Bound
LOCUS OF ACTION
“RECEPTORS”TISSUE RESERVOIRS
SYSTEMIC CIRCULATION
Free Drug
Bound Drug
ABSORPTION EXCRETION
BIOTRANSFORMATIONwww.freelivedoctor.com
![Page 98: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/98.jpg)
WHY BE CONCERNED ABOUT HOW DRUGS WORK?
• FDA Approved and Unapproved Uses
• Interactions with Other Drugs
• Adverse Effects and Contraindications
AIDS MEMORIZATION OF:
www.freelivedoctor.com
![Page 99: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/99.jpg)
WHY BE CONCERNED ABOUT HOW DRUGS WORK?
• Better assessment of new modalities for using drugs
• Better assessment of new indications for drugs
• Better assessment of new concerns regarding risk-benefit
AIDS EVALUATION OF MEDICAL LITERATURE:
www.freelivedoctor.com
![Page 100: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/100.jpg)
WHY BE CONCERNED ABOUT HOW DRUGS WORK?
The patient has more respect for and trust in a therapist whocan convey to the patient how the drug is affecting the patient’s body.
AIDS PATIENT-DOCTOR RELATIONSHIP:
A patient who understands his/her therapy is more inclined to become an active participant in the management of the patient’s disease.
www.freelivedoctor.com
![Page 101: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/101.jpg)
WHY BE CONCERNED ABOUT HOW DRUGS WORK?
Knowledge of how a drug works increases the therapist’s confidence that the drug is being used appropriately.
PEACE OF MIND!
www.freelivedoctor.com
![Page 102: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/102.jpg)
HOW DO DRUGS WORK?
• Some antagonize, block or inhibit endogenous proteins
• Some activate endogenous proteins
• A few have unconventional mechanisms of action
Most work by interacting withendogenous proteins:
www.freelivedoctor.com
![Page 103: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/103.jpg)
HOW DO DRUGS ANTAGONIZE, BLOCK OR INHIBIT ENDOGENOUS PROTEINS?
• Antagonists of Cell Surface Receptors
• Antagonists of Nuclear Receptors
• Enzyme Inhibitors
• Ion Channel Blockers
• Transport Inhibitors
•Inhibitors of Signal Transduction Proteins
www.freelivedoctor.com
![Page 104: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/104.jpg)
A macromolecular component of the organism that binds the drug and initiates its effect.
Definition of RECEPTOR:
Most receptors are proteins that have undergone various post-translational modifications such as covalent attachments of carbohydrate, lipid and phosphate.
www.freelivedoctor.com
![Page 105: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/105.jpg)
A receptor that is embedded in the cell membrane and functionsto receive chemical information from the extracellular compartment and to transmit that information to the intracellular compartment.
Definition of CELL SURFACE RECEPTOR:
www.freelivedoctor.com
![Page 106: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/106.jpg)
HOW DO DRUGS WORK BY ANTAGONIZING CELL SURFACE RECEPTORS? KEY CONCEPTS:
• Cell surface receptors exist to transmit chemical signals from the outside to the inside of the cell.
• Some compounds bind to cell surface receptors, yet do not activate the receptors to trigger a response.
• When cell surface receptors bind the molecule,the endogenous chemical cannot bind to the receptor and cannot trigger a response.
• The compound is said to “antagonize” or “block” the receptor and is referred to as a receptor antagonist.
www.freelivedoctor.com
![Page 107: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/107.jpg)
Footnote:
Most antagonists attach to binding site on receptor for endogenous agonist and sterically prevent endogenous agonist from binding. If binding is reversible - Competitive antagonistsIf binding is irreversible - Noncompetitive antagonists However, antagonists may bind to remote site on receptor and cause allosteric effects that displace endogenous agonist or prevent endogenous agonist from activating receptor. (Noncompetitive antagonists)
HOW DO DRUGS WORK BY ANTAGONIZING CELL SURFACE RECEPTORS?
www.freelivedoctor.com
![Page 108: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/108.jpg)
ARE DRUGS THAT ANTAGONIZE CELL SURFACE RECEPTORSCLINICALLY USEFUL?
• Angiotensin Receptor Blockers (ARBs) for high blood pressure, heart failure, chronic renal insufficiency(losartan [Cozaar®]; valsartan [Diovan®])
Some important examples:
• Beta-Adrenoceptor Blockers for angina, myocardial infarction, heart failure, high blood pressure, performance anxiety(propranolol [Inderal®]; atenolol [Tenormin®])
www.freelivedoctor.com
![Page 109: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/109.jpg)
ARE DRUGS THAT ANTAGONIZE NUCLEAR RECEPTORSCLINICALLY USEFUL?
• Mineralocorticoid Receptor Antagonists for edema due toliver cirrhosis and for heart failure(spironolactone [Aldactone®])
Some important examples:
• Estrogen Receptor Antagonists for the prevention and treatment
of breast cancer (tamoxifen [Nolvadex®])
www.freelivedoctor.com
![Page 110: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/110.jpg)
HOW DO DRUGS ANTAGONIZE, BLOCK OR INHIBIT ENDOGENOUS PROTEINS?
• Antagonists of Cell Surface Receptors
• Antagonists of Nuclear Receptors
• Enzyme Inhibitors
• Ion Channel Blockers
• Transport Inhibitors
•Inhibitors of Signal Transduction Proteins
www.freelivedoctor.com
![Page 111: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/111.jpg)
HOW DO DRUGS WORK BY INHIBITING ENZYMES?
Active Enzyme
Substrate Product
Cellular Function
Inactive Enzyme
Substrate
Bound Enzyme Inhibitor (Drug)
www.freelivedoctor.com
![Page 112: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/112.jpg)
HOW DO DRUGS WORK BY INHIBITING ENZYMES?KEY CONCEPTS:
• Enzymes catalyze the biosynthesis of products from substrates.
• Some drugs bind to enzymes and inhibit enzymatic activity.
• Loss of product due to enzyme inhibition mediates theeffects of enzyme inhibitors.
www.freelivedoctor.com
![Page 113: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/113.jpg)
ARE DRUGS THAT INHIBIT ENZYMESCLINICALLY USEFUL?
• Cyclooxygenase Inhibitors for pain relief,particularly due to arthritis (aspirin; ibuprofen [Motrin®])
Some important examples:
• Angiotensin Converting Enzyme (ACE) Inhibitors for high blood pressure, heart failure, and chronic renal insufficiency(captopril [Capoten®]; ramipril [Altace®])
• HMG-CoA Reductase Inhibitors for hypercholesterolemia(atorvastatin [Lipitor®]; pravastatin [Pravachol®])
www.freelivedoctor.com
![Page 114: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/114.jpg)
HOW DO DRUGS ANTAGONIZE, BLOCK OR INHIBIT ENDOGENOUS PROTEINS?
• Antagonists of Cell Surface Receptors
• Antagonists of Nuclear Receptors
• Enzyme Inhibitors
• Ion Channel Blockers
• Transport Inhibitors
•Inhibitors of Signal Transduction Proteins
www.freelivedoctor.com
![Page 115: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/115.jpg)
ARE DRUGS THAT BLOCK ION CHANNELSCLINICALLY USEFUL?
• Calcium Channel Blockers (CCBs) for angina and high blood pressure(amlodipine [Norvasc®]; diltiazem [Cardizem®])
Some important examples:
• Sodium Channel Blockers to suppress cardiac arrhythmias(lidocaine [Xylocaine®]; amiodarone [Cordarone®])
www.freelivedoctor.com
![Page 116: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/116.jpg)
ARE DRUGS THAT INHIBIT TRANSPORTERSCLINICALLY USEFUL?
• Selective Serotonin Reuptake Inhibitors (SSRIs) for thetreatment of depression (fluoxetine [Prozac®]; fluvoxamine [Luvox®])
Some important examples:
• Inhibitors of Na-2Cl-K Symporter (Loop Diuretics) inrenal epithelial cells to increase urine and sodium output for the treatment of edema (furosemide [Lasix®]; bumetanide [Bumex®])
www.freelivedoctor.com
![Page 117: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/117.jpg)
• Tyrosine Kinase Inhibitors for chronic myelocytic leukemia(imatinib [Gleevec®])
Some important examples:
• Type 5 Phosphodiesterase Inhibitors for erectile dysfunction(sildenafil [Viagra®])
• This is a major focus of drug development
ARE DRUGS THAT INHIBIT SIGNAL TRANSDUCTION PROTEINSCLINICALLY USEFUL?
www.freelivedoctor.com
![Page 118: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/118.jpg)
HOW DO DRUGS WORK BY ACTIVATING ENDOGENOUS PROTEINS?
• Agonists of Cell Surface Receptors(e.g. alpha-agonists, morphine agonists)
• Agonists of Nuclear Receptors(e.g. HRT for menopause, steroids for inflammation)
• Enzyme Activatorse.g. nitroglycerine (guanylyl cyclase), pralidoxime
• Ion Channel Openerse.g. minoxidil (K) and alprazolam (Cl)
www.freelivedoctor.com
![Page 119: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/119.jpg)
HOW DO CHEMICALS WORK BY ACTIVATING CELL SURFACE RECEPTORS?KEY CONCEPTS:
• Cell surface receptors exist to transmit chemical signals from the outside to the inside of the cell.
• Some chemicals bind to cell surface receptors and trigger a response.
• Chemicals in this group are called receptor agonists.
• Some agonists are actually the endogenous chemical signal,whereas other agonists mimic endogenous chemical signals.
www.freelivedoctor.com
![Page 120: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/120.jpg)
HOW DO CHEMICALS WORK BY UNCONVENTIONAL MECHANISMS OF ACTION?
• Disrupting of Structural Proteins e.g. vinca alkaloids for cancer, colchicine for gout
• Being Enzymes
e.g. streptokinase for thrombolysis
• Covalently Linking to Macromoleculese.g. cyclophosphamide for cancer
• Reacting Chemically with Small Moleculese.g. antacids for increased acidity
• Binding Free Molecules or Atomse.g. drugs for heavy metal poisoning, infliximab (anti-TNF)
www.freelivedoctor.com
![Page 121: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/121.jpg)
HOW DO DRUGS WORK BY UNCONVENTIONAL MECHANISMS OF ACTION (Continued)?
• Being Nutrientse.g. vitamins, minerals
• Exerting Actions Due to Physical Propertiese.g. mannitol (osmotic diuretic), laxatives
• Working Via an Antisense Actione.g. fomivirsen for CMV retininitis in AIDS
• Being Antigens e.g. vaccines
•Having Unknown Mechanisms of Actione.g. general anesthetics
www.freelivedoctor.com
![Page 122: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/122.jpg)
Characteristics of Drug-Receptor InteractionsCharacteristics of Drug-Receptor InteractionsCharacteristics of Drug-Receptor InteractionsCharacteristics of Drug-Receptor Interactions
• Chemical Bond: ionic, hydrogen, hydrophobic, Van der Waals, and covalent.
• Saturable• Competitive• Specific and Selective • Structure-activity relationships• Transduction mechanisms
• Chemical Bond: ionic, hydrogen, hydrophobic, Van der Waals, and covalent.
• Saturable• Competitive• Specific and Selective • Structure-activity relationships• Transduction mechanisms
www.freelivedoctor.com
![Page 123: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/123.jpg)
www.freelivedoctor.com
![Page 124: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/124.jpg)
NH4+-CH2(n)-NH4
+
www.freelivedoctor.com
![Page 125: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/125.jpg)
Receptor Transduction MechanismsReceptor Transduction MechanismsReceptor Transduction MechanismsReceptor Transduction Mechanisms
• Ion channel linked receptors e.g. Ach nicotinic (Na+) and GABA (Cl-)
• Second messenger generation, adenylate cyclase stimulation or inhibition - cAMP,guanylate cyclase - cGMP,phospholipase C - IP3, DAG• Some receptors are themselves protein kinases• Intracellular receptors (e.g. corticosteroids, thyroid
hormone)
• Ion channel linked receptors e.g. Ach nicotinic (Na+) and GABA (Cl-)
• Second messenger generation, adenylate cyclase stimulation or inhibition - cAMP,guanylate cyclase - cGMP,phospholipase C - IP3, DAG• Some receptors are themselves protein kinases• Intracellular receptors (e.g. corticosteroids, thyroid
hormone)
www.freelivedoctor.com
![Page 126: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/126.jpg)
k1
D + R <=> DR k2
By Law of Mass Action: [D]•[R]•K1= [DR]•K2
Therefore K2 /K1= Kd = [D]•[R]/[DR]
If RT = total # of receptors, thenRT = [R] + [DR]
Replace [R] by (RT-[DR]) and rearrange: [DR] [D]
RT Kd + [D]=
OCCUPATION THEORY OF DRUG-RECEPTOR INTERACTIONS
EFFECT
effectMax. effect=
www.freelivedoctor.com
![Page 127: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/127.jpg)
www.freelivedoctor.com
![Page 128: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/128.jpg)
Receptor Binding %
Bou
nd
Concentration of Ligand
Kd
www.freelivedoctor.com
![Page 129: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/129.jpg)
[D] (concentration units)
[DR
]/R
T
0.01 0.10 1.00 10.00 100.000.00
0.25
0.50
0.75
1.00
Kd=1kd=5
Kd=0.5
Compounds Have Different Affinities for the Same Receptor
www.freelivedoctor.com
![Page 130: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/130.jpg)
Competitive Noncompetitive
Types of Receptor Antagonistswww.freelivedoctor.com
![Page 131: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/131.jpg)
www.freelivedoctor.com
![Page 132: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/132.jpg)
[D] (concentration units)
% M
axim
al E
ffec
t
0.01 0.10 1.00 10.00 100.00 1000.000.0
0.2
0.4
0.6
0.8
1.0
Partial agonist
Full Agonist
Partial agonist
PARTIAL AGONISTS - EFFICACY
Even though drugs may occupy the same # of receptors, the magnitude of their effects may differ.
www.freelivedoctor.com
![Page 133: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/133.jpg)
www.freelivedoctor.com
![Page 134: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/134.jpg)
Drug (D)
Ri
DRi DRa
Ra
CONFORMATIONAL SELECTION
HOW TO EXPLAIN EFFICACY?
The relative affinityOf the drug to either conformation will determine the effect of the drug
www.freelivedoctor.com
![Page 135: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/135.jpg)
R
R1*
R2*
R3*
R R
R1*
R1*
R2*
R2*
R3*
R3*
www.freelivedoctor.com
![Page 136: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/136.jpg)
Spare Receptors
www.freelivedoctor.com
![Page 137: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/137.jpg)
Receptor RegulationReceptor RegulationReceptor RegulationReceptor Regulation
• Sensitization or Up-regulation1. Prolonged/continuous use of receptor blocker2. Inhibition of synthesis or release of hormone/neurotransmitter - Denervation
• Desensitization or Down-regulation1. Prolonged/continuous use of agonist2. Inhibition of degradation or uptake of agonist
Homologous vs. HeterologousUncoupling vs. Decreased Numbers
• Sensitization or Up-regulation1. Prolonged/continuous use of receptor blocker2. Inhibition of synthesis or release of hormone/neurotransmitter - Denervation
• Desensitization or Down-regulation1. Prolonged/continuous use of agonist2. Inhibition of degradation or uptake of agonist
Homologous vs. HeterologousUncoupling vs. Decreased Numbers
www.freelivedoctor.com
![Page 138: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/138.jpg)
www.freelivedoctor.com
![Page 139: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/139.jpg)
www.freelivedoctor.com
![Page 140: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/140.jpg)
www.freelivedoctor.com
![Page 141: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/141.jpg)
GRADED DOSE-RESPONSE CURVE
ED50
ED50
www.freelivedoctor.com
![Page 142: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/142.jpg)
QUANTAL DOSE-RESPONSE CURVE
Frequency Distribution
CumulativeFrequency Distribution
www.freelivedoctor.com
![Page 143: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/143.jpg)
www.freelivedoctor.com
![Page 144: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/144.jpg)
Morphine
Aspirin
www.freelivedoctor.com
![Page 145: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/145.jpg)
THERAPEUTIC INDEX – AN INDEX OF SAFETY
Hypnosis Death
www.freelivedoctor.com
![Page 146: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/146.jpg)
Margin of Safety = LD1
ED99
ED50AED99A
LD1A
www.freelivedoctor.com
![Page 147: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/147.jpg)
Causes of Variability in Drug ResponseCauses of Variability in Drug ResponseCauses of Variability in Drug ResponseCauses of Variability in Drug Response
Those related to the biological system
1. Body weight and size
2. Age and Sex
3. Genetics - pharmacogenetics
4. Condition of health
5. Placebo effect
Those related to the biological system
1. Body weight and size
2. Age and Sex
3. Genetics - pharmacogenetics
4. Condition of health
5. Placebo effect
www.freelivedoctor.com
![Page 148: Drug actions](https://reader035.vdocument.in/reader035/viewer/2022062404/5549b984b4c905fc7f8b4c2e/html5/thumbnails/148.jpg)
Causes of Variability in Drug ResponseCauses of Variability in Drug ResponseCauses of Variability in Drug ResponseCauses of Variability in Drug Response
• Those related to the conditions of administration1. Dose, formulation, route of administration.2. Resulting from repeated administration of drug:
drug resistance; drug tolerance-tachyphylaxis; drug allergy
3. Drug interactions:chemical or physical; GI absorption; protein binding/distribution; metabolism (stimulation/inhibition); excretion (ph/transport processes); receptor (potentiation/antagonism); changes in pH or electrolytes.
• Those related to the conditions of administration1. Dose, formulation, route of administration.2. Resulting from repeated administration of drug:
drug resistance; drug tolerance-tachyphylaxis; drug allergy
3. Drug interactions:chemical or physical; GI absorption; protein binding/distribution; metabolism (stimulation/inhibition); excretion (ph/transport processes); receptor (potentiation/antagonism); changes in pH or electrolytes.
www.freelivedoctor.com